Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • Market updates: JAMA study: DES benefits outweigh risks

    After more than two years of clinical data linking drug-eluting stents (DES) with an increased risk of stent thrombosis compared to their bare-metal cousins, a study in the Journal of the American Medical Association (JAMA) may shed some positive light on the DES space.
  • Agreements

    Cook Medical; HealthTrust Purchasing Group; Freescale Semiconductor; Monebo Technologies; HemCon Medical Technologies; SanguiBioTech; LifeScan; ResMed; Johnson & Johnson; IDev Technologies; YMed; Positron; Disease Management; NuView Radiopharmaceuticals
  • Business developments: Boston Sci sells most of private portfolio

    In a move that could help offset its $458 million 4Q07 Gudiant-related losses, Boston Scientific (Natick, Massachusetts) reported last month that it had signed a definitive agreement to sell its investments in a portfolio of companies, subject to certain closing and other conditions, to Saints Capital (San Francisco), a secondary direct-investment firm.
  • Acquisitions

    Applera; Celera; Berkeley HeartLab; Abbott Laboratories; Applied Biosystems; Invitrogen; Escalon Medical; Drew Scientific; JAS Diagnostics; Kardia Health Systems; Freeland Systems; Pediatrix Medical Group
  • International report: European cardiologists pushing good habits

    It takes a team to change the high-risk lifestyle habits of a single individual according to a large-scale study conducted by the European Society of Cardiology (ESC; Sophia Antipolis, France) published in the June 14 issue of The Lancet.
  • Medtronic's left-heart CRT lead is okayed

    Medtronic (Minneapolis) in mid-June received FDA approval of its Attain StarFix OTW (over-the-wire) lead. The company said it's the first active fixation left-heart lead for cardiac resynchronization therapy (CRT) and that the lead has demonstrated a 0% chronic (meaning more than one day post-implant) dislodgement rate.
  • Airport to staircase, Medtronic steps up big at HRS sessions

    SAN FRANCISCO Big medical companies usually have big footprints at medical conferences, and Medtronic stomped around with one of the very largest CD&D has ever seen at this year's scientific sessions of the Heart Rhythm Society (HRS; Washington).
  • Full July 1, 2008 Issue in PDF

  • What happened? Report reveals differing practices

    Two Epidemiologic Intelligence Service officers from the Centers for Disease Control and Prevention visited the Endoscopy Clinic of Southern Nevada in Las Vegas to investigate cases of hepatitis C and noted lapses in injection safety. Practices differed among the nurse anesthetists. This is an excerpt of their report:
  • Unsafe injections point to poor 'safety climate'

    At the Endoscopy Clinic of Southern Nevada in Las Vegas, it was not uncommon for a nurse anesthetist to remove the needle from a syringe and reuse the syringe even on another patient, public health investigators report.